-
The Peptide Moat: Who Actually Controls the Post-Patent GLP-1 Supply Chain?
1. The Molecule: Why You Can’t Just “Print” a GLP-1 To understand why the GLP-1 boom is generating such massive B2B wealth, you first have to understand why generic pharmaceutical companies can’t just churn out semaglutide the way they do paracetamol or blood pressure pills. The barrier to entry isn’t just the expired patent—it’s the…
-
Decoding Zaynich: A Deep Dive into Wockhardt’s AMR Breakthrough
When Wockhardt’s Zaynich recently secured US FDA approval, it achieved two historic milestones: offering a life-saving defense against severe, drug-resistant infections, and becoming the first indigenously developed Indian new chemical entity to clear the FDA. In this deep dive, we explore the clinical need it addresses, the underlying science of its beta-lactam enhancer mechanism, the…
-
Subscribe
Subscribed
Already have a WordPress.com account? Log in now.
Therapeutic Bridge 